|
The Affymax board of directors is made up of individuals with significant
experience starting, building and financing biotechnology companies.
Their experience brings breadth and depth from many vantage points
of the biotechnology and pharmaceutical industries.
R. Lee Douglas
Independent Biotechnology Consultant and Visiting Scholar, University of California, Berkeley
Nicholas Galakatos, Ph.D. (Lead Director)
General Partner, MPM BioVentures II and Managing Director, Clarus Ventures LLC
Christi van Heek
Managing Director, BIO POINT Group
Kathleen LaPorte
Managing Director, New Leaf Venture Partners
Keith Leonard
President and CEO, Kythera Biopharmaceuticals
Ted W. Love, M.D.
Independent Member of Board of Directors
Arlene M. Morris
President and CEO, Affymax, Inc.
Hollings C. Renton
Independent Member of Board of Directors
Daniel K. Spiegelman
Senior Vice President and CFO, CV Therapeutics, Inc.
John P. Walker
CEO, iZumi Bio, Inc.
R. Lee Douglas
Independent Biotechnology Consultant and Visiting Scholar, University of California, Berkeley
Mr Douglas has served as a member of our board of directors since 2004 and as a member of our Compensation Committee since July 2006. Since 1998, Mr. Douglas has been an independent consultant to biotechnology companies. Since 2002, he also has been a visiting scholar in the Molecular & Cell Biology Department at the University of California, Berkeley. Mr. Douglas was a co-founder of COR Therapeutics, Inc., a biotechnology company, and served in a variety of capacities there from 1988 to 1998, including as its chief executive officer from 1988 to 1990, chief financial officer from 1990 to 1992 and vice president of Corporate Development from 1990 to 1998. Mr. Douglas serves as a member of the board of directors of two privately held biotechnology companies. Mr. Douglas holds an M.B.A. from Harvard Business School, a Masters in City & Regional Planning from Harvard Graduate School of Design and a B.A. from the University of North Carolina, Charlotte.
Top
Nicholas Galakatos, Ph.D. (Lead Director)
General Partner, MPM BioVentures II and Managing Director, Clarus Ventures LLC
Dr. Galakatos has served as a member of our board of directors since 2001. Dr. Galakatos has served as the lead director and as the chair of our Nominating and Corporate Governance Committee since July 2006. Dr. Galakatos has been a general partner of MPM BioVentures II GP, LP since 2000, and managing director at Clarus Ventures LLC, a venture capital firm he co-founded in 2005. From 1997 to 2000, Dr. Galakatos served as vice president of New Businesses at Millennium Pharmaceuticals, a pharmaceutical company. From 1993 to 1997, Dr. Galakatos was an associate at Venrock Associates, a venture capital firm. From 1988 to 1993, Dr. Galakatos served as head of Molecular Biology Research and venture manager in Corporate Planning at Novartis, a pharmaceutical company. Dr. Galakatos currently serves as a member of the board of directors of several privately held biopharmaceutical companies. Dr. Galakatos is a member of several advisory councils at Harvard Medical School and MIT. Dr. Galakatos holds a Ph.D. from the Massachusetts Institute of Technology, performed post-doctoral work at Harvard Medical School, and holds a B.A. from Reed College.
Top
Christi van Heek
Managing Director, BIO POINT Group
Ms. van Heek has served as a member of our board of directors since 2007 and as a member of our Nominating and Corporate Governance Committee since March 2008. Ms. van Heek is currently managing director of BIO POINT Group, a business development company she founded in 2003. From 1991 to 2003, Ms. van Heek served in various roles at Genzyme, Inc., a biotechnology company, most recently as corporate officer and president, Therapeutics Division. In addition, she has held various sales and marketing positions at Genentech, Inc. and Caremark/HHCA, both biotechnology companies. Ms. van Heek also currently serves on the board of directors for a privately held company. She received her M.B.A. from Lindenwood University in St. Louis and holds a B.S.N. from the University of Iowa.
Top
Kathleen LaPorte
Managing Director, New Leaf Venture Partners
Ms. LaPorte has served as a member of our board of directors since 2001 and a member of our Compensation Committee since 2003. Since 2005, Ms. LaPorte has served as managing director of New Leaf Venture Partners, a venture capital firm, of which she was a founding partner. From 1994 to 2005, Ms. LaPorte served as general partner of Sprout Group, a venture capital firm, which she joined in 1993. From 1987 to 1993, Ms. LaPorte served as an employee at Asset Management Company, a venture capital firm, most recently as a principal. Ms. LaPorte currently serves as a member of the board of directors of ISTA Pharmaceuticals, Inc., a pharmaceutical company, Transcept Pharmaceuticals, Inc., a pharmaceutical company, and several privately held companies. Ms. LaPorte holds an M.B.A. from Stanford University Graduate School of Business, and a B.S. from Yale University.
Top
Keith Leonard
President and CEO, Kythera Biopharmaceuticals
Mr. Leonard has served as a member of our board of directors since December 2007 and as a member of our Audit Committee since March 2008. Mr. Leonard is currently president and chief executive officer and a director of Kythera Biopharmaceuticals, a biopharmaceutical company he founded in 2005. Prior to Kythera, Mr. Leonard served 13 years in various roles at Amgen, Inc., a biotechnology company, most recently as senior vice president, Amgen Europe from 2001 to 2004. Mr. Leonard currently serves on the board of directors of ARYx Therapeutics, a pharmaceutical company. Mr. Leonard holds an M.B.A. from the University of California, Los Angeles; an M.S. in engineering from the University of California, Berkeley; a B.A. in history from the University of Maryland; and a B.S. in engineering from the University of California, Los Angeles.
Top
Ted W. Love, M.D.
Independent Member of Board of Directors
Dr. Love has served as a member of our board of directors since June 2006 and as a member of our Audit Committee since July 2006. From 2001 to 2009, Dr. Love served as the president, chief executive officer and member of the board of directors of Nuvelo, Inc., a biopharmaceutical company, and as chairman of Nuvelo’s board of directors from 2005 to 2009, prior to its merger with ARCA biopharma, Inc. From 1998 to 2001, Dr. Love served as senior vice president of Development at Theravance, Inc. (formerly Advanced Medicine, Inc.), a biopharmaceutical company. From 1992 to 1998, Dr. Love served as a research physician and vice president of Product Development at Genentech, Inc., a biotechnology company. Dr. Love also serves as a member of the board of directors of Santarus, Inc., a pharmaceutical company, and ARCA biopharma, Inc., a biopharmaceutical company. Dr. Love holds an M.D. from Yale Medical School and a B.A. from Haverford College.
Top
Arlene M. Morris
President and CEO, Affymax, Inc.
Ms. Morris has served as our president and chief executive officer and as a member of our board of directors since 2003. From 2001 to 2003, Ms. Morris served as president and chief executive officer at Clearview Projects, an advisory firm to biopharmaceutical and biotechnology companies on strategic transactions. From 1996 to 2001, Ms. Morris served as senior vice president of Business Development at Coulter Pharmaceutical, Inc., a pharmaceutical company. From 1993 to 1996, Ms. Morris served as vice president of Business Development at Scios Inc., a biopharmaceutical company. From 1977 to 1993, Ms. Morris held positions of increasing responsibility at Johnson & Johnson, including vice president of Business Development for McNeil Pharmaceutical. Ms. Morris serves as a member of the board of directors of MediciNova, Inc., a biopharmaceutical company, and Phenomix Corporation, a biopharmaceutical company, and as a member of the board of directors of the Biotechnology Industry Organization. Ms. Morris holds a B.A. from Carlow College and has studied marketing at Western New England College.
Top
Hollings C. Renton
Independent Member of Board of Directors
Mr. Renton has served as a member of our board of directors since June 2009. Mr. Renton retired as chairman of the board at Onyx Pharmaceuticals, Inc., a biopharmaceutical and biotherapeutics company, in March 2008, where he also served as president and chief executive officer from 1993 and as director from 1992. Prior to joining Onyx, Mr. Renton was the president and chief operating officer of Chiron Corporation, a pharmaceutical company. He assumed that position in 1991 on Chiron’s acquisition of Cetus Corporation, a biotechnology company, where he had been president since 1990 and chief operating officer since 1987. He joined Cetus Corporation in 1981 and was chief financial officer from 1983 to 1987. Mr. Renton currently serves as a member of the board of directors of Rigel Pharmaceuticals, a pharmaceutical company, Cepheid Corporation, a molecular diagnostics company, and the Special Olympics of Northern California. Mr. Renton holds an M.B.A. from the University of Michigan and a B.S. in mathematics from Colorado State University.
Top
Daniel K. Spiegelman
Senior Vice President and CFO, CV Therapeutics, Inc.
Mr. Spiegelman has served as a member of our board of directors and our Audit Committee since September 2006. Mr. Spiegelman has served as the chair of our Audit Committee since December 2006. Since 1998, Mr. Spiegelman has been employed at CV Therapeutics, Inc., a biopharmaceutical company, and currently serves as its senior vice president and chief financial officer. From 1992 to 1998, Mr. Spiegelman was an employee at Genentech, Inc., a biotechnology company, most recently as treasurer. Mr. Spiegelman also serves as a member of the board of directors of Cyclacel Pharmaceuticals, Inc., a biotechnology company, and Oncothyreon, Inc., a biotechnology company. Mr. Spiegelman holds an M.B.A. and a B.A. from Stanford University.
Top
John P. Walker
CEO, iZumi Bio, Inc.
Mr. Walker has served as a member of our board of directors since 2006. Mr. Walker has been a member of our Nominating and Corporate Governance Committees since July 2006 and a member of our Compensation Committee since March 2007. Mr. Walker has served as the chair of our Compensation Committee since January 2008. From July 2006 until March 2008, Mr. Walker also served as a member of our Audit Committee. In February 2009, Mr. Walker assumed the position of chief executive officer of iZumi Bio, Inc., a company focused on the development of inducible stem cell technology. From 2006 to 2009, Mr. Walker served as chief executive officer of Novacea, Inc., a pharmaceutical company, which merged with Transcept Pharmaceuticals, Inc., a pharmaceutical company, in January 2009. Since 2001, Mr. Walker, acting as a consultant, served as an investment advisor to MDS Capital Corp., a venture capital firm, interim chief executive officer of KAI Pharmaceuticals, a pharmaceutical company, chairman and interim executive officer at Guava Technologies, a biotechnology company, chairman and chief executive officer of Bayhill Therapeutics, a biotechnology company, and chairman and interim chief executive officer of Centaur Pharmaceuticals, Inc., a pharmaceutical company. From 1993 to 2001, he was chairman, chief executive officer and a director of Axys Pharmaceuticals Inc. and its predecessor company, Arris Pharmaceutical Corporation, a pharmaceutical company. Mr. Walker currently serves as a member of the board of directors of Transcept Pharmaceuticals, Inc., Evotec AG, a drug discovery and development company, and several privately held biotechnology companies. Mr. Walker is a graduate of the Advanced Executive Program at the Kellogg School of Management at Northwestern University and holds a B.A. from the State University of New York at Buffalo.
Top |
